Skip to main content
← Science / Explained

SERIES: MYTHS READ AGAINST THE SCIENCE

The molecule is identical on paper, the supply chain is not

Where the Difference Lives

A research-use or not-for-human-consumption label is not an FDA approval. FDA has warned about unapproved GLP-1 products sold with research-purpose labeling, and about quality, dosing, labeling, salt-form, storage, and counterfeit risks in unapproved or compounded GLP-1 products.

Two vials labeled "semaglutide" can come from very different supply chains with very different verification standards.

What the FDA Has Flagged

The FDA has published specific concerns about unapproved GLP-1 products: dosing errors, fraudulent products, mismatches in the form of the molecule (the salt form, where different chemical pairings of the active ingredient with a stabilizer affect both the dose math and the stability), labeling problems, and quality-control gaps.

The molecule's name on the vial doesn't carry information about any of those.

What this means

References1 sources

How to read these sources

This article uses primary sources and reviews to separate mechanism, human evidence, and context.

Public UpdateNews or announcements
Show 4 more source types
Official LabelRegulator documents
Human TrialStudies in people
ReviewExpert synthesis
MechanismCell and pathway logic
  1. Public Update

    FDA.gov: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    U.S. Food and Drug Administration

    U.S. Food and Drug Administration · 2026 FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss Read source

    Used Here For

    Grounding the sourcing question in the FDA's own advisory on unapproved GLP-1 peptide products.

    Good For

    The regulator's documented concerns about unapproved peptide sourcing and quality.

    Not For

    Evaluating any single specific supplier or product; the advisory speaks to the category, not one brand.

    FDA.gov, content current as of September 1, 2026